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Abstract
Background
Genetic risk factors, intestinal microbiota and a dysregulated immune system contribute to
the pathogenesis of inflammatory bowel disease (IBD). We have previously demonstrated
that dysfunction of protein tyrosine phosphatase non-receptor type 2 (PTPN2) and PTPN22
contributes to alterations of intestinal microbiota and the onset of chronic intestinal inflam-
mation in vivo. Here, we investigated the influence of PTPN2 and PTPN22 gene variants on
intestinal microbiota composition in IBD patients.
Methods
Bacterial DNA from mucosa-associated samples of 75 CD and 57 UC patients were
sequenced using 16S rRNA sequencing approach. Microbial analysis, including alpha diver-
sity, beta diversity and taxonomical analysis by comparing to PTPN2 (rs1893217) and
PTPN22 (rs2476601) genotypes was performed in QIIME, the phyloseq R package and
MaAsLin pipeline.
Results
In PTPN2 variant UC patients, we detected an increase in relative abundance of unassigned
genera from Clostridiales and Lachnospiraceae families and reduction of Roseburia when
compared to PTPN2 wild-type (WT) patients. Ruminoccocus was increased in PTPN22 vari-
ant UC patients. In CD patients with severe disease course, Faecalibacterium, Bilophila,
Coprococcus, unclassified Erysipelotrichaeceae, unassigned genera from Clostridiales and
Ruminococcaceae families were reduced and Bacteroides were increased in PTPN2 WT
carriers, while Faecalibacterium, Bilophila, Coprococcus, and Erysipelotrichaeceae were
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reduced in PTPN22 WT patients when compared to patients with mild disease. In UC
patients with severe disease, relative abundance of Lachnobacterium was reduced in
PTPN2 and PTPN22 WT patients, Dorea was increased in samples from PTPN22 WT carri-
ers and an unassigned genus from Ruminococcaceae gen. was increased in patients with
PTPN2 variant genotype.
Conclusions
We identified that IBD-associated genetic risk variants, disease severity and the interaction
of these factors are related to significant alterations in intestinal microbiota composition of
IBD patients.
Introduction
The gut microbiota is vital for several critical host physiological processes including digestion
of dietary factors, development of the host immune system, and colonization resistance against
invading pathogens[1–3]. An alteration of the gut microbial composition has been associated
with the development of various intestinal and extraintestinal disorders, including inflamma-
tory bowel disease (IBD) [4–6]. Crohn’s disease (CD) and ulcerative colitis (UC), the major
IBD sub-types, represent phenotypically different diseases in terms of sites of intestinal
involvement, histopathology and clinical characteristics [7, 8]. However, there are intermedi-
ate forms and genetic linkages show substantial overlaps between CD, UC and other autoim-
mune and inflammatory conditions. Recent studies suggest a crucial role of intestinal
microbiota together with environmental factors in the genetically susceptible host conse-
quently resulting in chronic intestinal inflammation [7, 9].
To date, more than 240 IBD risk genes (e.g. NOD2, CARD9, ATG16L1, IRGM, TNFSF15,
GPR65, IL23R, IL12B and TTC7A) have been identified and many of them are involved in the
regulation of host-microbiota interactions [10–12]. Among those risk genes, protein tyrosine
phosphatase non-receptor type 2 (PTPN2) as well as PTPN22 are well-studied. While single
nucleotide polymorphisms (SNP) in PTPN2 are a risk factor for the onset of CD as well as UC,
SNP rs2476601 within the gene locus encoding PTPN22 protects from CD [13–15].
We have previously demonstrated that PTPN2 is involved in maintaining intestinal epithe-
lial barrier function, regulating autophagosome function and immune responses to invading
bacteria in intestinal cells, limiting pro-inflammatory cytokine secretion in the intestine as well
as controlling differentiation and function of CD4+ T-cells in vivo [16]. Hereby, the presence
of the IBD-associated PTPN2 variant promotes a pro-inflammatory phenotype [16–22]. Of
particular interest, we found that the presence of the disease-associated PTPN2 variant in
patients from the Swiss IBD Cohort Study (SIBDCS) is associated with a more severe disease
course, in particular increased frequency of pancolitis and intestinal surgery in UC patients,
however a better treatment response to anti-TNF antibodies in both CD and UC patients [23].
We also showed that mice deficient for PTPN2 in CD4+ T-cells compartment have altered
intestinal microbiota composition with a similar trend as observed in IBD patients [16].
In the intestine of CD patients, mRNA and protein levels of PTPN22 are mostly downregu-
lated resulting in attenuated IFN-gamma signalling [24]. Our recent data demonstrate that
PTPN22 is a critical regulator of the NLRP3 inflammasome by controlling NLRP3 tyrosine
phosphorylation [25]. Further, we found that PTPN22 controls NLRP3-mediated IL-1beta
secretion in an autophagy dependent manner [26]. In SIBDC patients suffering from CD, the
PTPN variants modulate intestinal microbiota
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presence of the protective PTPN22 allele was associated with less use of steroids and antibiotics
and reduced prevalence of vitamin D and calcium deficiency [27].
The role of the microbiota for developing and maintaining the immune system as well as in
the pathogenesis of IBD has been well documented [11, 28–30]. Aberrant intestinal microbiota
compositions, often referred to as intestinal dysbiosis, in UC patients is characterized by a
decreased microbial diversity within the individual gut microbiota [29, 30]. In addition, UC
has been described to have a distinct phylogenetic fingerprint with enrichment in putative
beneficial indicator bacteria, such as Proteobacteria and Fusobacterium, and decreased abun-
dance of protective indicator bacteria, such as Lachnospiraceae, Ruminococcaceae, Bifidobacter-
ium, Roseburia and Sutterella [31, 32]. In CD patients, a depletion of beneficial bacteria, such
as Firmicutes, Bifidobacterium or Clostridia and an increase in taxa from Bacteroidetes and
Enterobacteria are the main characteristics of altered intestinal microbiota [33, 34]. In addi-
tion, it was shown that mutations in several IBD susceptibility genes lead to impaired immune
responses to commensal bacteria, and subsequently to an imbalance in the taxonomic compo-
sition of the intestinal microbiota [12]. However, it has not been yet investigated whether
PTPN2 and PTPN22 gene variants are associated with intestinal microbiota changes in IBD
patients.
In the present study, we aimed to investigate the relevance of genetic variations in the IBD
risk genes PTPN2 and PTPN22 for intestinal microbiota composition and disease course in
CD and UC patients.
Materials and methods
Cohorts and study design
Most IBD studies have focused on fecal bacteria (non-invasive sampling method for gut
microbial characterization), instead of mucosa-associated bacteria, although the mucosal
microbiota is in closer proximity to intestinal immune system. Even though fecal microbiota
may simply be a numerical transformation of the mucosa-associated microbiota, microbial
comparisons of mucosa-associated samples and fecal samples showed that these two compart-
ments have significantly different microbial communities [35, 36] Hence, we have decided to
investigate the gut microbial profile of IBD patient at the disease site.
Patient mucosa-associated samples and data were entirely extracted from the register of the
nationwide Swiss IBD cohort study (SIBDCS) which comprises more than 3500 patients from
all regions of Switzerland [37]. The SIBDCS is an observational cohort study funded by the
Swiss National Science Foundation for research (Grant N˚ 3347CO-108792/1) started in 2006
by collaboration of the five university hospitals of Switzerland and subsequently including gas-
troenterologists working in smaller hospitals or private practice, finally covering the whole
country. Since then, at least one third of the current 3500 patients have been followed prospec-
tively for more than 10 years (data from March 2017) [37]. We have collected 941 biopsies of
346 IBD patients for microbial characterization of these patients in the presence of PTPN2 and
PTPN22 variants.
Ethics statement
The SIBDCS has been approved by the respective ethics committees in Switzerland. The lead
ethics committee is the Cantonal Ethics Committee of Zu¨rich (KEK Zurich: EK-1316). The
presented study is part of the research plan of the SIBDCS which means that no separate ethi-
cal approval was necessary for this project and the project is approved under the EK-1316
approval. Basic demographic data, clinical data and information about possible confounders
of microbiota analysis such as age, gender, BMI, medication were collected at the time of
PTPN variants modulate intestinal microbiota
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inclusion for all patients. All patients signed an informed consent and confirmed their partici-
pation in the cohort study at the time of enrolment and gave informed consent for data collec-
tion and analysis for research purposes. The current sub-study has been evaluated and
approved by the scientific board of SIBDC.
DNA extraction from human biopsies
Intestinal endoscopic biopsies from different location along gut of each patient were initially
collected into 2 ml microfuge tubes containing RNAlater (Sigma-Aldrich) and stored at -80˚C
prior to DNA extraction protocol that was carried out using AllPrep DNA/RNA Mini Kit
(Qiagen) according to the manufacturer’s instructions [38]. Briefly, 600 μL of Buffer RLT Plus
β-mercaptoethanol with a metal bead were added into each tube. Samples were then homoge-
nized using the Retsch Tissue Lyser (Qiagen) at 30/frequency for 3 min and followed by 3 min
centrifugation at maximum speed (Eppendorf). Supernatants were transferred into all Prep
DNA mini spin column and centrifuged at 10.000 rpm for 30 sec. DNA attached to spin col-
umns (Qiagen) were washed/de-salted using 500 μl of Buffer AW1 and Buffer AW2. Then,
DNA samples were eluted with 30 μl EB buffer (Qiagen) into 1.5 ml microfuge tubes. The con-
centrations and purity of the isolated DNA was evaluated using NanoDrop1
(ThermoScientific).
Definition of mild and severe disease course
Classification of disease severity was based on parameters suggested by Peyrin-Biroulet et al. as
well on data availability in the SIBDC database [39]. In detail, we included the following
patient parameters: history of intestinal surgery, steroid-dependent/steroid-refractory disease
or at least 6 months continuous treatment with corticosteroids (prednisone, prednisolone, cor-
tisol), use of at least two anti-TNF antibodies, pancolitis in UC patients or the presence of L4,
B2 or B3 according to disease location involvement (L1:ileal, L2:colonic, L3:ileocolonic, L4:
upper gastrointestinal) and disease behavior (B1:inflammatory, B2:stricturing, and B3:pene-
trating–both internal and perianal) based on Montreal classification in CD patients as well as
hospitalization due to IBD [40–42]. A mild disease course was defined by the absence of any of
those clinical criteria and a severe disease course was defined by the presence of at least one of
those clinical criteria.
Microbial profiling of biopsies and multivariate statistical analyses
Ileum and colon biopsies of each patient were processed and were sequenced for the V5/V6
region of the 16S rRNA genes with the barcoded forward primer in combination with the
reverse primer, as described elsewhere [43]. The 16s PCR amplicons were pooled at 26pM and
was prepared for sequencing on the Ion torrent PGM system according to the manufacturer’s
instructions (ThermoFisher) [44].
Raw sequences of samples with over 5000 reads were first loaded into the QIIME 1.9.1 pipe-
line, as described [45]. Sequences were initially clustered into ~350,000 taxa based on their
shared sequence similarity at 3% sequence divergence. Operational taxonomic units (OTUs)
were picked using UCLUST with a 97% sequence identity threshold followed by taxonomy
assignment using the latest Greengenes database from May, 2013. (http://greengenes.
secondgenome.com/downloads).
Further analysis of alpha diversity (Observed OTUs, Simpson and Shannon index) and beta
diversity (Bray-Curtis dissimilarities) were performed in the phyloseq pipeline using R (v3.4)
including vegan [46], multtest [47], and graphed via the ggplot2 packages [48]. The non-
parametric Mann-Whitney U-tests used to assess alpha diversity and Adonis from vegan
PTPN variants modulate intestinal microbiota
PLOS ONE | https://doi.org/10.1371/journal.pone.0199664 July 2, 2018 4 / 19
package (Permanova method on distances; 9999 permutations used for F-tests based on con-
tinuous sums of squares from permutations of the original data) were used to assess the statis-
tical significance of groups for beta diversity analysis. A p-value < 0.05 was considered
significant. Multivariate homogeneity of groups dispersions analysis calculated the average dis-
tance of test groups and identified whether the dispersions of the groups were similar and
p>0.05 value in this analysis was considered as the samples had the same dispersion.
The associations of microbial abundances (at phylum and genus levels) with clinical meta-
data and PTPN variants were analyzed using multivariate analysis by linear models (MaAsLin)
R package [49]. A false discovery rate (FDR; Benjamini-Hochberg false discovery rate correc-
tion) of 0.05, taxa present in at least 30% of the samples and OTUs that had more than %
0.0001 of total counts were set as the cut-off value for significance. Significant taxa were plotted
as arcsin(x)-square root transformed microbial relative abundances.
Results
Demographic aspects
Swiss IBD cohort study (SIBDCS) comprises ~1000 patients from all regions of Switzerland
that have been followed prospectively for more than 10 years. In order to characterize the
microbial community of IBD patients, among those patients, we have selected IBD patients
that were sampled at more than one location along the cephalocaudal axis of the distal gut dur-
ing the time attending for colonoscopy. We have initially processed 941 biopsy samples of 346
IBD patients obtained from the cohort. 314 of the 941 samples were initially excluded from
further analysis due to insufficient number of reads (<5000). Further exclusion criteria were
the age of the patients (samples in the range of 1st and 3rd quartiles of overall population) and
gender balance, since we aimed at obtaining a homogenous distribution. Lastly, we set our
focus on ileum and colon (combination of ascending colon, transversal colon, and descending
colon) biopsy samples for microbiota analysis. Filtering out low-quality samples (samples with
mean quality score <25) with excluding non-bacterial reads (filtered with filter_taxa_from_o-
tu_table.py command in QIIME) after balancing the age/gender variables to eliminate the
cofounder effect we generated high-quality reads (44057 reads per sample in average for CD
and 30696 reads per samples for UC group) of 292 samples from ileum and colon biopsies of
75 CD patients (24–45 years old) and 57 UC patients (28–52 years old). The extensive informa-
tion on all clinical characteristics and medication use are presented in Table 1.
IBD-associated risk variants have a direct impact on gut microbial profile
We initially used the genotype information of the IBD-associated risk variants rs1893217
within the PTPN2 gene locus and rs2476601 within the PTPN22 gene locus for investigating
the effect of these variants on gut microbial changes of IBD patients. Even though PTPN22 is
significantly associated with the risk of developing CD, but has no association with UC we
have included this variant in our analysis to see whether it has any effect on shaping micro-
biota of UC patients [50]. The respective genotyping had already been previously performed
by the SIBDC. The PTPN2 polymorphism rs1893217 [51] occurs in homozygous wild-type
(TT), heterozygous (CT) and homozygous variant (CC) genotypes while the PTPN22 poly-
morphism rs2476601 [52] occurs in homozygous wild-type (GG), heterozygous (GA) and
homozygous variant (AA) genotypes. Due to the low number of homozygous variant numbers
(1–3 patients) in each IBD-associated risk variant, homozygous variants were included into
heterozygous variant category.
We first identified the microbial features associated with disease phenotype and IBD-associ-
ated risk variant rs1893217 within the PTPN2 gene locus and rs2476601 within the PTPN22
PTPN variants modulate intestinal microbiota
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gene using MaAsLin pipeline that takes into account the possible effect of clinical metadata as
confounding factors in microbiota analysis and runs statistical analysis accordingly. We ran
the association analysis of a specific microbial community member with clinical metadata
(Table 1) including age, gender, body-mass index (BMI), anatomic location, tissue inflamma-
tion status, disease treatment categorized according to administration of anti-TNF-α agents or
systemic corticosteroids. We detected no significant differences in alpha diversity metrics
including Shannon index, Observed OTU and Simpson Index for CD (Fig 1A and Fig A in S1
Fig) and UC patients (Fig 1B and Fig B in S1 Fig) when analyzed individually for each risk
Table 1. Clinical characteristics of Swiss IBD cohort patients in numbers.
CD UC
Number of Patient (Number of Biopsies) 75 (144) 57 (148)
Gender (% female) 61 60
Mean age at enrolment (years +/-SD) 33.8 (+/-7.8) 40.8 (+/-7.1)
Mean age at diagnosis (years +/- SD) 23.6 (+/-7) 30.5 (+/-7.7)
PTPN2 (TT—CT) 55–20 41–16
PTPN22 (GG—GA) 64–11 51–6
Mean BMI
Normal (<25 Kg/m2) 57 39
Overweight (>25 Kg/m2, <30 Kg/m2) 14 13
Obese (>30 Kg/m2) 4 4
Unknown - 1
Mean disease duration at enrolment (years +/- SD) 10.2 (+/-8.3) 10.3 (+/-6.8)
Anatomic Location (Ileum—Colon) 33–42 26–31
Endoscopical Assessment
Inflamed / Non-inflamed 35 / 109 40 / 108
Disease behaviour (Montre´al Classification)
Inflammatory (B1) 34 -
Stricturing (B2) 20 -
Penetrating (B3) 20 -
Unknown 1 -
Disease location
CD
Ileum (L1) 26 -
Colon (L2) 17 -
Ileum & Colon (L3) 8 -
Upper GI Involvement (L4) 2 -
Unknown 2 2
UC
Proctitis - 11
Left-sided colitis - 19
Pancolitis - 26
Medical treatment (current)
Anti-TNF-α agents 21 7
Systemic corticosteroids 22 11
5-ASA 7 20
Methotrexate 3 -
Thiopurines 11 18
Number of patient in complete remission 67 45
https://doi.org/10.1371/journal.pone.0199664.t001
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variants. However, we noted a wider range of baseline community diversity for those in homo-
zygous wild-type (WT) genotypes. There was no significant difference in species richness and
diversity within the communities when different IBD-risk variant groups were compared.
However, the PCoA plots showed that gut microbial composition differentiated in PTPN2 var-
iant samples of CD patients (Adonis; p<0.01) (Fig 1C) but this was not the case for PTPN22
variant samples of CD patients (Adonis; p>0.05) (Fig 1E). In contrast, the PCoA plots showed
that gut microbial composition differentiated in PTPN2 and PTPN22 variants samples of UC
patients (Adonis; p<0.01) (Fig 1D and Fig 1F). The percentage on axis (varying from 7–10%)
showed the proportion of variance explained with PC1 or PC2 axis. We further analysed multi-
variate homogeneity of the groups on the basis of an appropriate measure of dissimilarity
which shows non-Euclidean distances between samples and group centroids. Beta dispersion
analysis showed that dispersion between CT and TT group in CD samples (p = 0.465), disper-
sion between CT and TT group in UC samples (p = 0.225) and dispersion between variant
allele and wild-type genotypes in UC samples (p = 0.285) were not significantly different (Fig
1C–1F). This allows us to conclude that the observed diversity between samples of variant
groups is not due to differences in group dispersions. Overall, PTPN2 variant associated with
changes on intestinal microbiota of CD and UC patients while PTPN22 variant affects only
intestinal microbiota of UC patients.
We next compared the relative abundances (% composition of a particular bacteria relative
to bacteria in the sample) of CD samples (S1 Table) and UC samples (S2 Table) with their
respective PTPN variant status. There were no taxa significantly different at phylum rank in
both disease conditions. However, at genus rank, several taxa were significantly different in
relative abundance according to genotype and disease status (Fig 2). There was an increase in
relative abundance of Clostridiales gen. and Lachnospiraceae gen. in CD patients with the CT
genotype in PTPN2 (Fig 2A and S1 Table). On the other hand, the relative abundance of Rose-
buria was reduced in UC patients carrying the CT genotype in PTPN2 gene (Fig 2B and S2
Table). Ruminoccocus was increased in UC patients carrying the GA genotype in PTPN22 var-
iant (Fig 2C and S2 Table) (BH adjusted-p < 0.05). In CD patients, when analyzed according
to their PTPN2 genotype, several bacteria including Bacteroides, Desulfovibrionaceae gen., Bifi-
dobacterium, Megasphaera, Mogibacteriaceae gen, Actinomyces, Erysipelotrichaceae_gen, Lach-
nospira, Oscillospira, Phascolarctobacterium, Akkermansia, and Roseburia showed trends of
relative abundance changes (p<0.05, BH adjusted-p > 0.05) (S1 Table). However, only a few
taxa, namely Epulopiscium, Neisseria, Lactococcus, and Rothia showed trends of relative abun-
dance changes (p<0.05, BH adjusted-p> 0.05) when analyzed according to PTPN22 genotype
(S1 Table). By contrast, there were a few taxa identified in UC patients showing the trends of
relative abundance changes (p<0.05, BH adjusted-p > 0.05). In addition, in UC patients, Pseu-
domonas, Staphylococcus, and Dialister showed a trend of relative abundance changes (p<0.05,
BH adjusted-p >0.05) when analyzed for PTPN2 genotypes (S2 Table), while Lactobacillus
showed a trend of relative abundance changes (p<0.05, BH adjusted-p >0.05) when analyzed
for PTPN22 genotype (S2 Table). Overall, this hints on that the presence of genetic risk vari-
ants within PTPN2 and PTPN22 might have a role on affecting the intestinal flora. However,
Fig 1. The microbial features associated with disease phenotype and IBD-associated risk variant rs1893217 and rs2476601. Species richness is calculated using
Shannon index in CD (A) and UC (B) samples. Beta diversity is calculated for CD (C) and UC (D) samples in the context of PTPN2 variant and for CD (E) and UC (F)
samples in the context of PTPN22 variant using Bray-Curtis dissimilarity matrix. Heterozygous variants are red color while homozygous wild-type ones are turquoise.
Colon samples are labeled as closed circle and ileum samples are labeled as closed triangles. Ellipses represent dispersion of samples and ellipses for colon samples are
labeled with straight line while ellipses for ileum samples are labeled are label dashed line. A p-value<0.05 is considered significant. Significant differences are marked
through the panels.
https://doi.org/10.1371/journal.pone.0199664.g001
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Fig 2. The microbial differences associated with disease and risk variants. The relative abundance of significantly different taxa (q<0.05) were plotted for
PTPN2 variant in (A) when analyzed for CD and in (B) when analyzed for UC. The relative abundance of significantly different taxa (q<0.05) was plotted for
PTPN22 variants when analyzed for UC (C) samples. The “gen.,” was used for the classification of a distinct but unnamed genus in the Greengenes reference
database and “unclassified” used for identification of unclassified taxa in Greengenes reference database, as previously used in another study [53].
https://doi.org/10.1371/journal.pone.0199664.g002
PTPN variants modulate intestinal microbiota
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the overall low number of samples in heterozygous genotypes may be considered as a plausible
reason underlying significant differences only in unadjusted testing in some genera analyzed.
Disease severity and its interaction with PTPN polymorphisms affect
several taxa
It has been documented that different complex microbiota can alter disease severity in mouse
models of IBD [54]. Therefore, we next analyzed whether gut microbial profiles of IBD
patients with different PTPN2 or PTPN22 variants were affected by disease severity.
We initially categorized disease severity into two categories, namely mild and severe sug-
gested by Peyrin-Biroulet et al.[39] and investigated whether IBD-associated risk variants and
disease severity are associated with gut microbiota alterations in CD and UC (Table 2). Of the
entire set of patients, we have mainly low number of samples in severe disease group of each
disease condition for patients with PTPN22 heterozygous variant. Due to the numbers of sam-
ples specifically in severe UC patients (< 3 patients) with heterozygous variant carriers, the
comparisons of microbial relative abundance in these groups were excluded from further
analysis.
In taxonomical analysis of CD patients, there were significant changes only observed in TT
but not CT genotype in PTPN2 (Fig 3A and S3 Table) and in GG but not GA genotype in
PTPN22 (Fig 3B and S4 Table) when compared according to disease severity status of the
patients. The relative abundances of Faecalibacterium, Bilophila, Coprococcus, unclassified Ery-
sipelotrichaeceae, Clostridales gen., and Ruminococcaceae gen., were reduced, while Bacteroides
taxa were increased in samples from CD patients with severe disease activity carrying PTPN2
TT genotype (BH adjusted-p <0.05) (Fig 3A). Moreover, relative abundances of Faecalibacter-
ium, Bilophila, Coprococcus, and unclassified Erysipelotrichaeceae were significantly reduced in
samples carrying GG genotype of PTPN22 (BH adjusted-p <0.05) (Fig 3B) from CD patients
with elevated disease severity.
In contrast, the number of changes in relative abundance in UC samples categorized
according to disease severity and IBD-associated risk variants were lower. The relative abun-
dance of Lachnobacterium was reduced in samples from patients with TT genotype of PTPN2
(Fig 3C and S5 Table) and GG genotype of PTPN22 (Fig 3D and S6 Table) with severe dis-
ease activity (BH adjusted-p <0.05), while Dorea was increased in samples from GG genotype
in PTPN22. In addition, the abundance of Ruminococcaceae gen. in UC samples from patients
with severe disease activity was significantly influenced by the host’s genetic makeup (BH
adjusted-p <0.05) (Fig 3E and S5 Table) since this taxon was not significantly different in
wild-type variant.
Discussion
In the present study, we analysed the effects of the IBD-associated variants within the gene loci
encoding PTPN2 and PTPN22 on intestinal microbiota composition. We found that the pres-
ence of variant alleles significantly affects intestinal microbiota composition. The intestinal
microbiota alteration was not only affected by PTPN genotypes, but it also was affected by
Table 2. The number of CD and UC patients within different disease severity condition and PTPN variants.
Disease Severity CD (Number of Patients) UC (Number of Patients)
CT / TT GA / GG CT / TT GA / GG
Mild 7 / 28 7 / 28 13 / 29 4 / 38
Severe 13 / 27 4 / 36 3 / 12 2 / 13
https://doi.org/10.1371/journal.pone.0199664.t002
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interaction of genotype and disease severity course suggesting a direct link for a genotype-
microbiota interaction affecting disease course in IBD patients.
Alterations in intestinal microbiota composition, so-called dysbiosis, have been associated
with a broad number of diseases, including obesity, diabetes, rheumatoid arthritis, asthma,
depression, malignant diseases, irritable bowel syndrome (IBS) and IBD [55]. Intestinal dys-
biosis is particularly one of the most important factors contributing to the onset of the IBD
subtypes, CD and UC [9] and a number of studies documented significant differences in intes-
tinal microbiota composition between healthy people and IBD patients [56, 57]. Although
there are some overlaps in the respective dysbiotic alterations, there are also considerable dif-
ferences in intestinal microbiota changes between both diseases [58–60]. Walker et al. demon-
strated that microbial diversity is reduced in UC and CD patients accompanied by a reduction
of Firmicutes and an increase in Bacteroidetes in all IBD patients and a selective elevation in the
abundance of Enterobacteriaceae in CD patients [59]. In UC patients an enrichment of putative
aggressive Proteobacteria and Fusobacterium spp. and a decreased abundance of protective
bacteria, such as Lachnospiraceae, Ruminococcaceae, Bifidobacterium spp. or Roseburia has
been shown [9]. Though a role for intestinal bacteria for the pathogenesis of IBD has been well
Fig 3. The microbial differences associated with disease severity within same PTPN disease variants. The relative abundance of significantly different microbial taxa
(q<0.05) were plotted according to disease severity status for PTPN2 wild-type variant in (A) and PTPN22 wild type variant in (B) when analyzed for CD. The relative
abundance of significantly different microbial taxa (q<0.05) were plotted according to disease severity status PTPN2 wild-type variant in (C) and heterozygous variant
(D) and PTPN22 wild-type variant in (E) when analyzed for UC.
https://doi.org/10.1371/journal.pone.0199664.g003
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described nowadays, the interplay between genetic risk factors and intestinal microbiota is less
clear [9]. Nevertheless, more and more evidence suggests that genetic IBD risk factors, in par-
ticular NOD2 and ATG16L1, critically interact with the intestinal microbiota to maintain
intestinal homeostasis and to control immune responses in the gastrointestinal tract [10, 11].
We have recently demonstrated that PTPN2 as well as PTPN22 regulate autophagosome
function, including ATG16L1 protein expression, and cell responses following activation of
NOD2 [17, 19, 61]. Furthermore, the presence of the IBD-associated genetic variants within
the gene loci encoding PTPN2 and PTPN22 affects the disease course in IBD patients and
PTPN2-deficient mice exhibit intestinal microbiota changes comparable to those observed in
IBD patients [16, 23, 27]. In good accordance with those previous observations, we found that
the presence of PTPN2 variant affects the gut microbial composition in UC and CD patients,
while the presence of the PTPN22 variant affects microbial composition mainly in UC
patients. On a genus level, the PTPN2 variant is associated with an increase in relative abun-
dance of Clostridiales gen. and Lachnospiraceae gen. in CD patients and a decrease in the rela-
tive abundance of Roseburia in UC patients. Further, we found the increased relative
abundance of Ruminoccocus in PTPN22 variant patients. In particular, the increased abun-
dance of Ruminoccocus in PTPN22 variant patients can be explained by the protective effect of
this variant. These data are of particular interest, since the physiologic role for PTPN2 and
PTPN22 in the intestinal tract suggests a crucial role for both of the phosphatases in regulating
immune responses to intestinal bacteria and in controlling the intestinal immune system.
Genetically caused alterations in PTPN2/PTPN22 protein function might therefore directly
contribute to the altered microbiota composition that favors the onset of IBD.
The aim of the present study was to determine whether the alterations in intestinal micro-
biota composition observed in mouse colitis models in T-cell specific PTPN2 deficient mice
[16] are comparable to the alterations in intestinal microbiota composition observed in IBD
patients. Our data clearly demonstrate comparable effects in PTPN2 knock-out mice and
PTPN2 variant carriers. We anticipate that this is due to PTPN2-mediated dysfunction of sev-
eral immune mechanisms that are important for the body’s immune response to luminal bac-
teria and for maintaining intestinal homeostasis. In particular, dysfunction of autophagy,
aberrant inflammasome activation and altered T-cell activation and differentiation seems to
play a crucial role for the observed correlation between PTPN2 dysfunction and alterations in
intestinal microbiota composition (Fig 4) [16, 17, 62].
We also found differences in intestinal microbiota composition between PTPN wild-type
genotype and heterozygous genotype samples of patients with severe disease course. These
observations hint on that altered expression levels and/or protein function of e.g. antimicrobial
molecules in patients featuring the heterozygous gene variants might have a role on controlling
these taxa in severe disease activity conditions. However, though those taxa were not signifi-
cantly different from each other in heterozygous variants, we must keep in mind that this
might be due to the fact that there were low number of samples from heterozygous variant
carriers.
Of interest, we found that Bacteroides was increased in samples with more severe disease
while Ruminococcaceae gen. was reduced in samples from severe CD patients with TT geno-
type in PTPN2. Further, we detected that the abundance of Ruminococcaceae gen. showed a
trend of reduction with severe disease activity in samples from UC patients with TT genotype
in PTPN2. This finding is of particular interest, since Ruminococcaceae gen. are regarded as
“good” bacteria and a reduction of those bacteria might be a part of the detrimental effect of
the PTPN2 variation in human disease. The reduction of Feaecalibacterium, Coprococcus and
Lachnobacterium in severe UC patients with the wild-type PTPN22 genotype makes sense in a
way that the reduction of those bacteria is regarded as being characteristic for the disease and
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the preservation of those bacteria in PTPN22 variant patients might be part of the protective
role of the PTPN22 variation in human disease.
Our results in addition seem to provide evidence for a causative role of intestinal microbial
alterations in patients with IBD as opposed to solely reflecting a sequela of inflammation
within the intestinal mucosa (the so called “chicken and egg” question). Our data further sug-
gest, that established risk genes associated with the development of IBD might profoundly
impact intestinal microbial composition irrespective of disease activity. Thus, our results point
in the same direction as the findings by other groups demonstrating, a microbiota-shaping
potential of the Nod2-gene[63], alterations in IBD-risk-gene carriers in the healthy population
[64], altered microbiota in siblings of CD patients [65] similar microbial alterations in
inflamed and non-inflamed mucosal compartments [32] and therefore indicate a causative
role of microbial alterations in IBD pathogenesis. However, the results also point towards a
Fig 4. Effects of PTPN2 dysfunction on intestinal microbiota composition. PTPN2-mediated dysfunction of several immune mechanisms that are important for the
body’s immune response to luminal bacteria and for maintaining intestinal homeostasis. In particular, dysfunction of autophagy, aberrant inflammasome activation and
altered T-cell activation and differentiation seems to play a crucial role for the observed correlation between PTPN2 dysfunction and alterations in intestinal microbiota
composition.
https://doi.org/10.1371/journal.pone.0199664.g004
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dominant role of disease severity over a certain genotype of the affected patient. Nevertheless,
the fact that in our study significant differences were found in mild vs. severe cases of CD in
patients only with WT genotypes may be, at least in part, related to the fact that CT (PTPN2)
or GA (PTPN22) groups became very small after stratification to mild and severe cases.
Overall, our data show that presence of the IBD-associated variations within the PTPN2
and PTPN22 gene loci are related to significant alterations in intestinal microbiota composi-
tion what clearly resembles our previous findings in mouse colitis models using PTPN2 defi-
cient mice. Further, variations within the PTPN2 gene loci are correlated with disease severity
in CD patients. Those findings suggest a critical role for PTPN2 and PTPN22 in modulating
intestinal microbiota composition and point towards a novel gene (PTPN2)-microbiota inter-
action directly affecting disease severity in IBD patients. In conclusion, our data indicate a
novel role for PTPN2 and PTPN22 in controlling intestinal microbiota composition and fur-
ther elucidate the complex interplay between genetic risk factors, intestinal microbiota and dis-
ease course in IBD patients.
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S1 Fig. Alpha diversity measurements in IBD samples. Observed OTU and Simpson index
are calculated for PTPN variants. Species richness are compared in (A) for CD samples and in
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S1 Table. Comparison of relative abundance of CD samples at phylum and genus rank cal-
culated using MaAsLin. Taxonomic difference of PTPN variants in CD disease group was
identified and significant and non-significant differences were recorded based on MaAsLin
output file. Table shows coefficient value for each taxa and number of samples that were ana-
lyzed. A p-value <0.05 is considered significant.
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S2 Table. Comparison of relative abundance of UC samples at phylum and genus rank cal-
culated using MaAsLin. Taxonomic difference of PTPN variants in UC disease group was
identified and significant and non-significant differences were recorded based on MaAsLin
output file. Table shows coefficient value for each taxa and number of samples that were ana-
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variants in CD samples using MaAsLin. Taxonomic difference of PTPN2 variants in CD dis-
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cant differences were recorded based on MaAsLin output file. Table shows coefficient value
for each taxa and number of samples that were analyzed. A p-value<0.05 is considered signifi-
cant.
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S4 Table. Comparison of relative abundances of different disease severities and PTPN22
variants in CD samples using MaAsLin. Taxonomic difference of PTPN22 variants in CD
disease group was identified based on the disease severity status and significant and non-sig-
nificant differences were recorded based on MaAsLin output file. Table shows coefficient
value for each taxa and number of samples that were analyzed. A p-value <0.05 is considered
significant.
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S5 Table. Comparison of relative abundances of different disease severities and PTPN2
variants in UC samples using MaAsLin. Taxonomic difference of PTPN2 variants in UC dis-
ease group was identified based on the disease severity status and significant and non-significant
differences were recorded based on MaAsLin output file. Table shows coefficient value for each
taxa and number of samples that were analyzed. A p-value<0.05 is considered significant.
(PDF)
S6 Table. Comparison of relative abundances of different disease severities and PTPN22 var-
iants in UC samples using MaAsLin. Taxonomic difference of PTPN22 variants in UC disease
group was identified based on the disease severity status and significant and non-significant dif-
ferences were recorded based on MaAsLin output file. Table shows coefficient value for each
taxa and number of samples that were analyzed. A p-value<0.05 is considered significant.
(PDF)
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